Facebook Twitter LinkedIn Instagram Email Printer Google Plus

Tobias Handschuh

Partner, Health and Life Sciences, Oliver Wyman

Some therapeutic sectors saw their compound annual growth rate drop 10% or more, deviating from long-term trends. Sales should return to normal growth trajectories as backlogs in procedures continue to clear out.

Partner, Health and Life Sciences, Oliver Wyman

Pharmaceutical giants are shedding business units with an eye toward focusing on their innovative pharma operations and targeted therapeutic areas.

Head of UK and Ireland Health and Life Sciences, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman